ANAnsel P. Nalin

Ansel P. Nalin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ansel P. Nalin has a total of 187 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    CD200R1 Marks a Branch Point During Human Natural Killer Cell Development in Tonsils

    by Youssef Youssef, Ansel P. Nalin, Michael A. Ruesch, Matthew R. Lordo, Noah T. Koenigs, David Clever, Joel Cesar, Megan Broughton, Wing Chan, Anthony G. Mansour, et al.

    SUMMARY: Human natural killer (NK) cells arise from common innate lymphoid cell progenitor and precursor populations that are selectively enriched within secondary lymphoid tissues and that complete their terminal differentiation through stages of progressively lineage-restricted downstream developmental intermediates. We identify two subsets of tonsil CD94/NKG2A + NKp80⁻ “stage 4A” NK cell development intermediates that show differential expression of the inhibitory receptor, CD200R1. Ex vivo single-cell transcriptomic, DNA methylation, phenotypic, and functional analyses demonstrate that CD200R1⁺ stage 4A cells represent an immature, oligopotent precursor population enriched for tissue-resident and cytokine-responsive programs. In contrast, CD200R1⁻ stage 4A cells show more restricted NK cell developmental potential concomitant with features of mature NK cells. These findings help to refine the human NK cell developmental pathway in tonsils and highlight CD200R1 as a useful marker delineating an uncommitted developmental state linking microenvironmental cues to NK cell maturation and plasticity.

  • Open Access

    Control arm overperformance in phase 3 oncology clinical trials

    by Ansel P. Nalin, Pavlos Msaouel, Adam J. Grippin, Ramez Kouzy, Joseph Abi Jaoude, Timothy A. Lin, Avital M. Miller, Noah S. Meimoun, Ethan B. Ludmir, Alexander D. Sherry

    Background: In randomized clinical trials (RCTs), anticipating control arm outcomes is important for power calculations and enrollment goals. Unexpected overperformance of the control arm can underpower RCTs. The objective of this study was to estimate the prevalence of control arm overperformance in phase 3 oncology RCTs. Methods: The authors conducted a meta‐epidemiological study of two‐arm, superiority‐design, phase 3 oncology RCTs. They reviewed articles/publications and protocols for power calculations, justification, and outcomes. Control arm performance was measured as the ratio of observed control arm outcomes relative to pretrial estimates, and overperformance was defined as a 10% improvement. Results: In total, 385 RCTs met inclusion criteria. The primary end point was overall survival (OS) in 134 RCTs (35%). Of 311 RCTs (81%) that provided a pretrial estimate for control arm performance, 138 RCTs (44%) cited a justification for the estimate. Greater than expected control arm performance was associated with lower odds of meeting the primary end point (adjusted odds ratio, 0.989; 95% confidence interval, 0.981–0.998; p = 0.015). Of 244 RCTs that were evaluable for control arm performance, 104 (43%) exhibited overperformance. RCTs that used OS as a primary end point were more likely to exhibit control arm overperformance compared with RCTs that used other primary end points (56% vs. 33%; adjusted odds ratio, 2.43; 95% confidence interval, 1.42–4.15; p = .001). Conclusions: Control arm overperformance is common in phase 3 oncology RCTs and is associated with trial outcomes, suggesting an effect on study power. Because overperformance appears to be especially prevalent when OS is the primary end point, the effects of postprogression therapies on OS may be underappreciated. Alternative strategies for designing trials should be considered for reliable estimation of treatment effects.


  • Open Access

    Supplementary Figure from Identification and Targeting of the Developmental Blockade in Extranodal Natural Killer/T-cell Lymphoma

    by Bethany L. Mundy-Bosse, Christoph Weigel, Yue-Zhong Wu, Salma Abdelbaky, Youssef Youssef, Susana Beceiro Casas, Nicholas Polley, Gabrielle Ernst, Karen A. Young, Kathleen K. McConnell, et al.

    Supplementary Figure from Identification and Targeting of the Developmental Blockade in Extranodal Natural Killer/T-cell Lymphoma

  • Open Access

    Supplementary Data from Identification and Targeting of the Developmental Blockade in Extranodal Natural Killer/T-cell Lymphoma

    by Bethany L. Mundy-Bosse, Christoph Weigel, Yue-Zhong Wu, Salma Abdelbaky, Youssef Youssef, Susana Beceiro Casas, Nicholas Polley, Gabrielle Ernst, Karen A. Young, Kathleen K. McConnell, et al.

    Supplementary Data from Identification and Targeting of the Developmental Blockade in Extranodal Natural Killer/T-cell Lymphoma

  • Open Access

    Supplementary Data from Identification and Targeting of the Developmental Blockade in Extranodal Natural Killer/T-cell Lymphoma

    by Bethany L. Mundy-Bosse, Christoph Weigel, Yue-Zhong Wu, Salma Abdelbaky, Youssef Youssef, Susana Beceiro Casas, Nicholas Polley, Gabrielle Ernst, Karen A. Young, Kathleen K. McConnell, et al.

    Supplementary Data from Identification and Targeting of the Developmental Blockade in Extranodal Natural Killer/T-cell Lymphoma

  • Open Access

    Data from Identification and Targeting of the Developmental Blockade in Extranodal Natural Killer/T-cell Lymphoma

    by Bethany L. Mundy-Bosse, Christoph Weigel, Yue-Zhong Wu, Salma Abdelbaky, Youssef Youssef, Susana Beceiro Casas, Nicholas Polley, Gabrielle Ernst, Karen A. Young, Kathleen K. McConnell, et al.

    Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive, rare lymphoma of natural killer (NK) cell origin with poor clinical outcomes. Here we used phenotypic and molecular profiling, including epigenetic analyses, to investigate how ENKTL ontogeny relates to normal NK-cell development. We demonstrate that neoplastic NK cells are stably, but reversibly, arrested at earlier stages of NK-cell maturation. Genes downregulated in the most epigenetic immature tumors were associated with polycomb silencing along with genomic gain and overexpression of EZH2. ENKTL cells exhibited genome-wide DNA hypermethylation. Tumor-specific DNA methylation gains were associated with polycomb-marked regions, involving extensive gene silencing and loss of transcription factor binding. To investigate therapeutic targeting, we treated novel patient-derived xenograft (PDX) models of ENKTL with the DNA hypomethylating agent, 5-azacytidine. Treatment led to reexpression of NK-cell developmental genes, phenotypic NK-cell differentiation, and prolongation of survival. These studies lay the foundation for epigenetic-directed therapy in ENKTL.Significance:Through epigenetic and transcriptomic analyses of ENKTL, a rare, aggressive malignancy, along with normal NK-cell developmental intermediates, we identified that extreme DNA hypermethylation targets genes required for NK-cell development. Disrupting this epigenetic blockade in novel PDX models led to ENKTL differentiation and improved survival.This article is highlighted in the In This Issue feature, p. 85

  • Open Access

    Supplementary Figure from Identification and Targeting of the Developmental Blockade in Extranodal Natural Killer/T-cell Lymphoma

    by Bethany L. Mundy-Bosse, Christoph Weigel, Yue-Zhong Wu, Salma Abdelbaky, Youssef Youssef, Susana Beceiro Casas, Nicholas Polley, Gabrielle Ernst, Karen A. Young, Kathleen K. McConnell, et al.

    Supplementary Figure from Identification and Targeting of the Developmental Blockade in Extranodal Natural Killer/T-cell Lymphoma

  • Open Access

    Data from Identification and Targeting of the Developmental Blockade in Extranodal Natural Killer/T-cell Lymphoma

    by Bethany L. Mundy-Bosse, Christoph Weigel, Yue-Zhong Wu, Salma Abdelbaky, Youssef Youssef, Susana Beceiro Casas, Nicholas Polley, Gabrielle Ernst, Karen A. Young, Kathleen K. McConnell, et al.

    Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive, rare lymphoma of natural killer (NK) cell origin with poor clinical outcomes. Here we used phenotypic and molecular profiling, including epigenetic analyses, to investigate how ENKTL ontogeny relates to normal NK-cell development. We demonstrate that neoplastic NK cells are stably, but reversibly, arrested at earlier stages of NK-cell maturation. Genes downregulated in the most epigenetic immature tumors were associated with polycomb silencing along with genomic gain and overexpression of EZH2. ENKTL cells exhibited genome-wide DNA hypermethylation. Tumor-specific DNA methylation gains were associated with polycomb-marked regions, involving extensive gene silencing and loss of transcription factor binding. To investigate therapeutic targeting, we treated novel patient-derived xenograft (PDX) models of ENKTL with the DNA hypomethylating agent, 5-azacytidine. Treatment led to reexpression of NK-cell developmental genes, phenotypic NK-cell differentiation, and prolongation of survival. These studies lay the foundation for epigenetic-directed therapy in ENKTL.Significance:Through epigenetic and transcriptomic analyses of ENKTL, a rare, aggressive malignancy, along with normal NK-cell developmental intermediates, we identified that extreme DNA hypermethylation targets genes required for NK-cell development. Disrupting this epigenetic blockade in novel PDX models led to ENKTL differentiation and improved survival.This article is highlighted in the In This Issue feature, p. 85

  • Open Access

    Supplementary Data from Identification and Targeting of the Developmental Blockade in Extranodal Natural Killer/T-cell Lymphoma

    by Bethany L. Mundy-Bosse, Christoph Weigel, Yue-Zhong Wu, Salma Abdelbaky, Youssef Youssef, Susana Beceiro Casas, Nicholas Polley, Gabrielle Ernst, Karen A. Young, Kathleen K. McConnell, et al.

    Supplementary Data from Identification and Targeting of the Developmental Blockade in Extranodal Natural Killer/T-cell Lymphoma

  • Open Access

    Supplementary Data from Identification and Targeting of the Developmental Blockade in Extranodal Natural Killer/T-cell Lymphoma

    by Bethany L. Mundy-Bosse, Christoph Weigel, Yue-Zhong Wu, Salma Abdelbaky, Youssef Youssef, Susana Beceiro Casas, Nicholas Polley, Gabrielle Ernst, Karen A. Young, Kathleen K. McConnell, et al.

    Supplementary Data from Identification and Targeting of the Developmental Blockade in Extranodal Natural Killer/T-cell Lymphoma